Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1729245

Cover Image

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1729245

Global Anticoccidial Drugs Market Size study, by Drug Class (Ionophore, Synthetic Drugs), by Drug Action (Coccidiostatic, Coccidiocidal), by Animal Type and Regional Forecasts 2022-2032

PUBLISHED:
PAGES: 285 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4950
Printable PDF (Enterprise License)
USD 6250

Add to Cart

Global Anticoccidial Drugs Market is valued at approximately USD 0.18 billion in 2023 and is anticipated to grow with a steady compound annual growth rate of more than 4.30% over the forecast period 2024-2032. Anticoccidial drugs form the cornerstone of modern veterinary parasite management strategies, particularly within the global poultry and livestock industries. These pharmacological agents are designed to combat coccidiosis-a parasitic disease with significant morbidity and mortality implications among farm animals. Acting either as coccidiostatic or coccidiocidal agents, these drugs support large-scale producers in maintaining productivity, ensuring animal welfare, and reducing economic losses. With intensifying global demand for animal protein and rising awareness about zoonotic disease prevention, the adoption of targeted anticoccidial therapies is accelerating in both developed and developing markets.

The steady expansion of the anticoccidial drugs market is largely being driven by increasing intensification of animal farming practices, especially within the poultry sector. Large commercial farms are placing greater emphasis on disease control to meet rising meat and egg demand efficiently and ethically. Meanwhile, synthetic and ionophore-based drugs remain central to this movement, with their ability to prevent outbreaks during the most susceptible phases of an animal's growth cycle. However, the growing concerns over antimicrobial resistance (AMR) and regulatory restrictions on the non-therapeutic use of feed-grade antibiotics are shifting the focus toward more judicious and strategic drug usage. As a result, manufacturers are exploring next-generation anticoccidial solutions that offer improved safety profiles and reduced resistance risk.

Furthermore, major pharmaceutical companies are leveraging advanced drug formulation technologies and real-time health monitoring platforms to deliver sustained-release and species-specific anticoccidial agents. These efforts aim to optimize drug efficacy while minimizing environmental and physiological side effects. Simultaneously, increased government scrutiny on residue levels and export regulations is encouraging the development of cleaner, metabolizable compounds. Strategic R&D investments and public-private collaborations across the veterinary drug landscape are likely to unlock new opportunities for market players striving to align with evolving animal health protocols and global trade standards.

Regionally, North America holds a dominant position in the anticoccidial drugs market, owing to its sophisticated veterinary infrastructure, early adoption of innovative parasiticides, and robust poultry farming industry. Europe closely follows, driven by strict animal health regulations and high awareness levels among farm operators. On the other hand, Asia Pacific is anticipated to emerge as the fastest-growing market, with countries like China, India, and Indonesia witnessing rapid expansion in poultry and ruminant production. This growth is underpinned by the rising disposable income, dietary protein shift, and supportive government initiatives for animal health management. Latin America and the Middle East & Africa are gradually joining this growth trajectory, albeit with infrastructure and accessibility constraints.

Major market player included in this report are:

  • Elanco Animal Health Incorporated
  • Huvepharma EOOD
  • Phibro Animal Health Corporation
  • Merck & Co., Inc.
  • Virbac
  • Ceva Sante Animale
  • Vetoquinol S.A.
  • Zydus Animal Health and Investments Ltd.
  • Boehringer Ingelheim International GmbH
  • Dechra Pharmaceuticals PLC
  • Kemin Industries, Inc.
  • Zoetis Inc.
  • Impextraco NV
  • Bayer AG
  • ECO Animal Health Group PLC

The detailed segments and sub-segment of the market are explained below:

By Drug Class

  • Ionophore
  • Synthetic Drugs

By Drug Action

  • Coccidiostatic
  • Coccidiocidal

By Animal Type

  • (Detailed segmentation to be provided as per available data)

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Anticoccidial Drugs Market Executive Summary

  • 1.1. Global Anticoccidial Drugs Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Drug Class (Ionophore, Synthetic Drugs)
    • 1.3.2. By Drug Action (Coccidiostatic, Coccidiocidal)
    • 1.3.3. By Animal Type
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Anticoccidial Drugs Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Stakeholder Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory Frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Stakeholder Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Anticoccidial Drugs Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Intensification of poultry and livestock production
    • 3.1.2. Rising global demand for animal protein
    • 3.1.3. Heightened focus on zoonotic disease prevention
  • 3.2. Market Challenges
    • 3.2.1. Antimicrobial resistance concerns
    • 3.2.2. Stringent regulatory restrictions on feed grade antibiotics
    • 3.2.3. Cost pressures in large scale farming operations
  • 3.3. Market Opportunities
    • 3.3.1. Development of next generation coccidiostatic agents
    • 3.3.2. Adoption of sustained release and species specific formulations
    • 3.3.3. Public-private collaborations for cleaner parasiticides

Chapter 4. Global Anticoccidial Drugs Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top Investment Opportunity
  • 4.4. Top Winning Strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Anticoccidial Drugs Market Size & Forecasts by Drug Class 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Anticoccidial Drugs Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Million)
    • 5.2.1. Ionophore
    • 5.2.2. Synthetic Drugs

Chapter 6. Global Anticoccidial Drugs Market Size & Forecasts by Drug Action 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Anticoccidial Drugs Market: Drug Action Revenue Trend Analysis, 2022 & 2032 (USD Million)
    • 6.2.1. Coccidiostatic
    • 6.2.2. Coccidiocidal

Chapter 7. Global Anticoccidial Drugs Market Size & Forecasts by Animal Type 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Global Anticoccidial Drugs Market: Animal Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
    • 7.2.1. Poultry
    • 7.2.2. Ruminants
    • 7.2.3. Others

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
    • 8.1.1. Elanco Animal Health Incorporated
    • 8.1.2. Merck & Co., Inc.
    • 8.1.3. Phibro Animal Health Corporation
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. Elanco Animal Health Incorporated
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Market Strategies
    • 8.3.2. Huvepharma EOOD
    • 8.3.3. Phibro Animal Health Corporation
    • 8.3.4. Virbac
    • 8.3.5. Ceva Sante Animale
    • 8.3.6. Vetoquinol S.A.
    • 8.3.7. Zydus Animal Health and Investments Ltd.
    • 8.3.8. Boehringer Ingelheim International GmbH
    • 8.3.9. Dechra Pharmaceuticals PLC
    • 8.3.10. Kemin Industries, Inc.
    • 8.3.11. Zoetis Inc.
    • 8.3.12. Impextraco NV
    • 8.3.13. Bayer AG
    • 8.3.14. ECO Animal Health Group PLC

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!